disorder, the authors included in their meta-analysis two of our studies, in which we reported that CBD reduces the anxiety induced by experimental models of acute stress. 2, 3 In their review, Black and colleagues mentioned that we found no significant improvement in anxiety symptoms with the use of CBD compared to placebo (pooled standardised mean difference [SMD] -0·87 [95% CI -2·01 to 0·27]; table 3 and appendix p53).
After a thorough reading of the article, we believe that the authors' conclusions with respect to the efficacy of CBD in social anxiety might have been influenced by inaccuracies in the description or analysis of the evidence available. Based on our raw data and the same primary outcome criteria (change in anxiety symptoms), we found that the pooled effect from our two studies showed a significant benefit of CBD compared to placebo in social anxiety (SMD -1·28 [95% CI -1·93 to -0·63; figure) . Including the doubleblind controlled trial (n=37) that examined the impact of daily CBD for 4 weeks in teenagers with social anxiety disorder, published in Nov, 2019, 4 the outcome of reduced anxiety associated with CBD use compared with placebo remained significant, with even bigger size effect (SMD -1·58 [95% CI -2·08 to -1·07]; I²= 22·4%).
We think that the authors of the review might have either included in their analysis the healthy controls LTvE reports grants from the Deutsche Forschungsgemeinschaft and from the Medical Faculty of the Albert-Ludwigs-University Freiburg, outside the submitted work and publications of books and presentations of educational talks with reference to the Position Paper. All other authors declare no competing interests. 
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Figure:
Raw data and forest plots with randomised controlled trial evidence on the effects of cannabidiol for treatment of social anxiety disorder N=sample size. CBD=cannabidiol. PL=placebo. SMD=standardised mean difference *Drug intake 0. †Re-stress 60'. ‡Pretest score. §Speech phase score.
We read with interest the article by Nicola Black and colleagues in The Lancet Psychiatry in which the authors showed that scarce evidence exists to suggest that cannabinoids improve mental disorders and their symptoms, including anxiety. 1 With respect to the effects of cannabidiol (CBD) in patients with social anxiety the risk of transition to a cannabis use disorder, a notion previously supported by several population-based longitudinal studies. 2 Nevertheless, as most available data concerning risk of transition to cannabis use disorders are based on recreational users, the extent of this risk among individuals who use medicinal cannabinoids is unknown. The use of oral cannabis-based medicines or inhaled cannabis strains with low tetrahydrocannabinol (THC) concentration, common in medical settings, is associated with decreased risk for developing cannabis use disorder compared with the use of inhaled cannabis strains with high THC concentration, common in recreational use. 3 However, the extent to which standard diagnostic tools and criteria for cannabis use disorder are applicable to those receiving the substance in a medical setting is unclear. Although long-term use of addictive substances (eg, prescription opioids) often leads to physical and psychological dependence, when used in a medical setting substantially lower rates of related aberrant behaviours, characteristic of addiction, are commonly observed. 4 These aberrant behaviours are part of the diagnostic criteria both in the American Psychiatric Association's Diagnostic and Statistical Manual (DSM-5) and in the WHO's International Classification of Diseases. To address this diagnostic challenge, alternative measures, such as the Opioid Related Behaviours In Treatment scale, 5 were developed and are commonly and efficiently used to assess additional aspects of problematic use of opioid pain medication.
Unfortunately, similar scales for medicinal cannabinoid users are currently unavailable. We believe that adapting screening and diagnostic tools for cannabis use disorders in individuals using medicinal cannabinoids is critical to assessing the risk of transition to problematic substance use in this patient population.
(n=12) that performed the Simulated Public Speaking Test and did not receive any medication, 3 or that they might have failed to consider the baseline versus stress conditions 2-3 of the sample, or that they did not take into consideration the cross-over design of the SPECT study. 2 The pharmacological treatment of social anxiety disorder remains problematic as less than optimal symptom remission is achieved with the use of available drugs. All such therapies have their disadvantages, since antidepressants have an initial activation and a long latency period of response and benzodiazepines are limited by their potential to induce sedation, motor impairment, and dependence and withdrawal symptoms following discontinuation. Hence, a clear need exists to explore new pharmacological possibilities for managing social anxiety disorder.
The anxiolytic effects of CBD are supported by both pre-clinical and clinical reports. CBD has an early onset of action and does not seem to induce significant adverse effects in humans. 5 Together, these findings lead to the hypothesis that CBD might have a therapeutic potential in the management of social anxiety disorder.
As opportunely highlighted by Black and colleagues, 1 cannabinoids must however be prepared according to good laboratory and manufacturing practices to be used in the development of drugs consistently produced and controlled by international standards. Likewise, randomised, double-blind, placebo-controlled clinical trials with larger samples and chronic administration are still necessary to ascertain the safety, adequate dose range, and efficacy of cannabinoids as medicines, in general and specifically in social anxiety disorder. JAC, AWZ, FSG and In their meta-analysis, Nicola Black and colleagues 1 point to a lack of clinical superiority in using cannabinoids for treatment of mental disorders and a significant increased risk for developing short-term adverse consequences. The authors suggest that long-term use of cannabinoids might also increase
